Ikon Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 0.44 M
as on 17-11-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.91 Cr
as on 17-11-2024
- Satisfied Charges ₹ 14.45 Cr
as on 17-11-2024
- Revenue 75.73%
(FY 2023)
- Profit -733.83%
(FY 2023)
- Ebitda 73.02%
(FY 2023)
- Net Worth -40.51%
(FY 2023)
- Total Assets -6.12%
(FY 2023)
About Ikon Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.44 M.
The company currently has active open charges totaling ₹16.91 Cr. The company has closed loans amounting to ₹14.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ashish Verma, Dinesh Panday, and Mradul Agarwal serve as directors at the Company.
- CIN/LLPIN
U93000UR2013PTC000769
- Company No.
000769
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jul 2013
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ikon Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Verma  | Director | 02-Jul-2013 | Current |
| Dinesh Panday | Director | 02-Jul-2013 | Current |
| Mradul Agarwal | Director | 02-Jul-2013 | Current |
Financial Performance of Ikon Pharmachem.
Ikon Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 75.73% increase. The company also saw a substantial fall in profitability, with a 733.83% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ikon Pharmachem?
Unlock access to Ikon Pharmachem's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 18 Nov 2023 | ₹16.91 Cr | Open |
Others Creation Date: 22 Mar 2022 | ₹4.50 M | Satisfied |
Others Creation Date: 21 Jan 2021 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Ikon Pharmachem?
Ikon Pharmachem has a workforce of 42 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ikon Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ikon Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
